The affirmation of Medtronic's patents by the U.S. Patent Office and the move to resume the trial against Axonics, coupled with the action to block infringing imports, are likely to positively impact Medtronic's stock in the short term. This development underscores Medtronic's strong position in protecting its intellectual property, which is crucial for its business in the competitive healthcare technology sector.